Start your own journey to clinic

Please provide us with a few details so that we can match you with the right expert in your field.


Thank you, your request has been received.

We're busy connecting you with an expert, who will be in touch as soon as possible.

Oops! Something went wrong while submitting the form. Please try again or email us at


Novel C-7 Carbon Substituted Fourth Generation Fluoroquinolones Targeting N.Gonorrhoea Infections

Fluoroquinolones (FQ) are a first-line antibacterial therapy, used to treat both Gram-negative and Gram-positive bacterial infections. FQ efficacy is achieved by disrupting the bacterial enzyme's DNA gyrase and topoisimerase IV. There is extensive SAR analysis of this class of antibiotics-both in terms of microbiological activity 1-3 and target related toxicity. Delafloxacin, a fourth generation FQ has broad spectrum activity and reduced FQ related toxicity 4-5. However, it has recently failed a phase 3 clinical trial for treatment of N.gonorrhoeae infections. This was due to lack of sufficient efficacy at the dose administered.

Alternatively, search our entire resource library below

Show filters
View all
Category one
Category two
Category three
Category four
Resource type
Related service line
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Showing 0 items
No results found.
There are no results with this criteria. Try changing your search.